The purpose of this clinical research study is to support earlier observations that Glucovance controls glucose levels after a mean, and improves overall glucose control better than metformin or glyburide therapy alone in adults with type 2 diabetes.

Condition	Treatment or Intervention	Phase
Diabetes Mellitus, Non-Insulin-Dependent	Drug: Glucovance (metformin HCl/glyburide)  Drug: or Metformin HCl alone  Drug: or Glyburide alone.	Phase IV

Ages Eligible for Study:  20 Years   -   75 Years,  Genders Eligible for Study:  Both

Criteria

Adults 20-75 with a diagnosis of type 2 diabetes mellitus who are not adequately controlled with diet and exercise, and have an HbA1c greater than 6.7%

Arkansas
      Local Institution, Little Rock,  Arkansas,  United States
California
      Local Institution, Los Angeles,  California,  United States
Illinois
      Local Institution, Chicago,  Illinois,  United States
Indiana
      Local Institution, Indianapolis,  Indiana,  United States
New York
      Local Institution, Brooklyn,  New York,  United States
      Local Institution, Rochester,  New York,  United States
Pennsylvania
      Local Institution, Pittsburgh,  Pennsylvania,  United States
Texas
      Local Institution, Dallas,  Texas,  United States
      Local Institution, San Antonio,  Texas,  United States

Study ID Numbers:  CV138-062
Record last reviewed:  February 2004
Last Updated:  October 13, 2004
Record first received:  May 3, 2002
ClinicalTrials.gov Identifier:  NCT00035568
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08